Natural killer cells and natural killer T cells in Lyme arthritis

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Katchar, Kia ^a,b   Drouin, Elise E ^a   Steere, Allen C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD94 ANTIGEN; CEFTRIAXONE; DOXYCYCLINE; GAMMA INTERFERON; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; CYTOKINE;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD; BORRELIA BURGDORFERI; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; HUMAN; LYME DISEASE; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SPIROCHETE; SYNOVIAL FLUID; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; CHEMISTRY; CHILD; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BORRELIA BURGDORFERI; CHILD; CYTOKINES; DRUG RESISTANCE, MICROBIAL; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYME DISEASE; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; SYNOVIAL FLUID; YOUNG ADULT;

EID: 84887068972     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4373     Document Type: Article

References (48)

1. Steere AC. Lyme disease. N Engl J Med 2001, 345:115-125. 10.1056/NEJM200107123450207, 11450660.
2. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987, 107:725-731. 10.7326/0003-4819-107-5-725, 3662285.
3. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH, Liu NY, Schmid CH. Treatment of Lyme arthritis. Arthritis Rheum 1994, 37:878-888. 10.1002/art.1780370616, 8003060.
4. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, Franklin M, Hilton E, Bryant GL, Agger WA, Maladorno D. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005, 117:393-397. 10.1007/s00508-005-0361-8, 16053194.
5. Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006, 54:3079-3086. 10.1002/art.22131, 17009226.
6. Jones KL, McHugh GA, Glickstein LJ, Steere AC. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: high frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum 2009, 60:2174-2182. 10.1002/art.24812, 2753280, 19565522.
7. Jones KL, Glickstein LJ, Damle N, Sikand VK, McHugh G, Steere AC. Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J Clin Microbiol 2006, 44:4407-4413. 10.1128/JCM.01077-06, 1698394, 17035489.
8. Wormser GP, Brisson D, Liveris D, Hanincova K, Sandigursky S, Nowakowski J, Nadelman RB, Ludin S, Schwartz I. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis 2008, 198:1358-1364. 10.1086/592279, 2776734, 18781866.
9. Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 2011, 63:2238-2247. 10.1002/art.30384, 21590753.
10. Strle K, Shin JJ, Glickstein LJ, Steere AC. Association of a toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum 2012, 64:1497-1507. 3338893, 22246581.
11. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006, 203:961-971. 10.1084/jem.20052471, 3212725, 16585267.
12. Iliopoulou BP, Guerau-de-Arellano M, Huber BT. HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum 2009, 60:3831-3840. 10.1002/art.25005, 2828865, 19950279.
13. Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 2012, 122:2652-2660. 10.1172/JCI58813, 3386809, 22728937.
14. Shen S, Shin JJ, Strle K, McHugh G, Li X, Glickstein LJ, Drouin EE, Steere AC. Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Arthritis Rheum 2010, 62:2127-2137. 2913315, 20506317.
15. Vudattu NK, Strle K, Steere AC, Drouin EE. Dysregulation of CD4 + CD25hi + T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis. Arthritis Rheum 2013, 65:1643-1654. 10.1002/art.37910, 23450683.
16. Drouin EE, Seward RJ, Strle K, McHugh G, Katchar K, Londono D, Yao C, Costello CE, Steere AC. A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum 2013, 65:186-196. 10.1002/art.37732, 23044924.
17. Lanier LL. Shades of grey-the blurring view of innate and adaptive immunity. Nat Rev Immunol 2013, 13:73-74. 10.1038/nri3389, 23469373.
18. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol 2011, 11:645-657. 10.1038/nri3044, 21869816.
19. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465. 10.1111/j.1365-2567.2008.03027.x, 2673358, 19278419.
20. Shegarfi H, Naddafi F, Mirshafiey A. Natural killer cells and their role in rheumatoid arthritis: friend or foe?. ScientificWorldJournal 2012, 2012:491974. 3322405, 22547986.
21. Moretta L. Dissecting CD56dim human NK cells. Blood 2010, 116:3689-3691. 10.1182/blood-2010-09-303057, 21071612.
22. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013, 13:101-117. 10.1038/nri3369, 23334244.
23. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817-890. 10.1146/annurev.immunol.22.012703.104608, 15032598.
24. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011, 11:131-142. 10.1038/nri2904, 21267014.
25. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Beutler B, Wilson IA, Tsuji M, Sellati TJ, Wong CH, Kronenberg M. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006, 7:978-986. 10.1038/ni1380, 16921381.
26. Tupin E, Benhnia MR, Kinjo Y, Patsey R, Lena CJ, Haller MC, Caimano MJ, Imamura M, Wong CH, Crotty S, Radolf JD, Sellati TJ, Kronenberg M. NKT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci USA 2008, 105:19863-19868. 10.1073/pnas.0810519105, 2604993, 19060201.
27. Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, van Rooijen N, Chaconas G, Kubes P. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 2010, 11:295-302. 10.1038/ni.1855, 20228796.
28. Yakimchuk K, Roura-Mir C, Magalhaes KG, de Jong A, Kasmar AG, Granter SR, Budd R, Steere A, Pena-Cruz V, Kirschning C, Cheng TY, Moody DB. Borrelia burgdorferi infection regulates CD1 expression in human cells and tissues via IL1-beta. Eur J Immunol 2011, 41:694-705. 10.1002/eji.201040808, 3082368, 21246541.
29. Centers for Disease Control and Prevention Case definitions for public health surveillance. MMWR Morb Mortal Wkly Rep 1990, 39:1-43. Centers for Disease Control and Prevention.
30. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1089-1134. 10.1086/508667, 17029130.
31. Lima M, Teixeira MA, Queiros ML, Leite M, Santos AH, Justica B, Orfao A. Immunophenotypic characterization of normal blood CD56 + lo versus CD56 + hi NK- cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood Cells Mol Dis 2001, 27:731-743. 10.1006/bcmd.2001.0443, 11778657.
32. Tarazona R, Casado JG, Delarosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Galiani MD, Gonzalez R, Solana R, Pena J. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002, 22:176-183. 10.1023/A:1015476114409, 12078859.
33. Strle K, Jones KL, Drouin EE, Li X, Steere AC. Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am J Pathol 2011, 178:2726-2739. 10.1016/j.ajpath.2011.02.018, 3123987, 21641395.
34. Mullegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, Steere AC. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 2000, 115:1115-1123. 10.1046/j.1523-1747.2000.00198.x, 11121150.
35. Salazar JC, Pope CD, Sellati TJ, Feder HM, Kiely TG, Dardick KR, Buckman RL, Moore MW, Caimano MJ, Pope JG, Krause PJ, Radolf JD. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003, 171:2660-2670.
36. Glickstein L, Moore B, Bledsoe T, Damle N, Sikand V, Steere AC. Inflammatory cytokine production predominates in early Lyme disease in patients with erythema migrans. Infect Immun 2003, 71:6051-6053. 10.1128/IAI.71.10.6051-6053.2003, 201073, 14500528.
37. Shin JJ, Glickstein L, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory Lyme arthritis. Arthritis Rheum 2007, 56:1325-1335. 10.1002/art.22441, 17393419.
38. Ben-Menachem G, Kubler-Kielb J, Coxon B, Yergey A, Schneerson R. A newly discovered cholesteryl galactoside from Borrelia burgdorferi. Proc Natl Acad Sci USA 2003, 100:7913-7918. 10.1073/pnas.1232451100, 164687, 12799465.
39. Jones KL, Seward RJ, Ben-Menachem G, Glickstein LJ, Costello CE, Steere AC. Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection. Clin Immunol 2009, 132:93-102. 10.1016/j.clim.2009.03.510, 2752957, 19342303.
40. Ahern DJ, Brennan FM. The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?. Immunol Lett 2011, 136:115-121. 10.1016/j.imlet.2010.11.001, 21073898.
41. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004, 173:6418-6426.
42. Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999, 118:131-136. 10.1046/j.1365-2249.1999.01018.x, 1905408, 10540170.
43. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:5941-5946. 10.1073/pnas.0601335103, 1458677, 16585503.
44. Parietti V, Chifflot H, Sibilia J, Muller S, Monneaux F. Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 2010, 134:331-339. 10.1016/j.clim.2009.11.007, 20022305.
45. Yoshiga Y, Goto D, Segawa S, Horikoshi M, Hayashi T, Matsumoto I, Ito S, Taniguchi M, Sumida T. Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol 2011, 164:236-247. 10.1111/j.1365-2249.2011.04369.x, 3087916, 21391989.
46. Horikoshi M, Goto D, Segawa S, Yoshiga Y, Iwanami K, Inoue A, Tanaka Y, Matsumoto I, Sumida T. Activation of Invariant NKT cells with glycolipid ligand alpha- galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis. PLoS One 2012, 7:e51215. 10.1371/journal.pone.0051215, 3520964, 23251456.
47. Stricker RB, Burrascano J, Winger E. Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease. Ann Agric Environ Med 2002, 9:111-113.
48. Marques A, Brown MR, Fleisher TA. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol 2009, 16:1249-1250. 10.1128/CVI.00167-09, 2725528, 19515868.